Increased Lymphocyte Infiltration in NSCLC Neoadjuvant Chemo-Immunotherapy Non-responders: A Biomarker of T-Cell Dysfunction and Prognosis?

Ann Surg Oncol. 2024 Jan;31(1):25-27. doi: 10.1245/s10434-023-14388-1. Epub 2023 Oct 29.

Authors

Gavitt A Woodard¹, Christina Cho², Lieping Chen²

Affiliations

¹ Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, Yale University, New Haven, CT, USA. gavitt.woodard@yale.edu.
² Department of Immunobiology, Yale University School of Medicine, Yale University, New Haven, CT, USA.

PMID: 37899411
DOI: 10.1245/s10434-023-14388-1

No abstract available

Publication types

Editorial

MeSH terms

Biomarkers
Humans
Immunotherapy
Lung Neoplasms* / drug therapy
Lymphocytes
Neoadjuvant Therapy*
Prognosis
T-Lymphocytes

Substances

Biomarkers